{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:23:33Z","timestamp":1791433413066,"version":"4.3.3"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jconrel.2015.02.030","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T00:42:50Z","timestamp":1424392970000},"page":"170-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-\u03baB-dependent inflammation process in a mouse model of Parkinson's disease"],"prefix":"10.1016","volume":"203","author":[{"given":"Eduardo","family":"Anitua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"P\u00e9rez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorka","family":"Orive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Carro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2015.02.030_bb0005","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson's disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"issue":"Suppl. 3","key":"10.1016\/j.jconrel.2015.02.030_bb0010","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/ana.10487","article-title":"Genetic and environmental factors in the cause of Parkinson's disease","volume":"53","author":"Warner","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.WNL.0000151960.28687.93","article-title":"Physical activity and the risk of Parkinson disease","volume":"64","author":"Chen","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson's disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2015.02.030_bb0025","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1002\/mds.22638","article-title":"Inflammation and Parkinson's disease pathogenesis","volume":"25","author":"Przedborski","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mds.23455","article-title":"Glia: initiators and progressors of pathology in Parkinson's disease","volume":"26","author":"Halliday","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0035","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/jlb.65.4.409","article-title":"Inflammation of the brain in Alzheimer's disease: implications for therapy","volume":"65","author":"McGeer","year":"1999","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0040","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1523\/JNEUROSCI.22-05-01763.2002","article-title":"Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease","volume":"22","author":"Wu","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","article-title":"Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease","volume":"19","author":"Zhang","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0050","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mds.21751","article-title":"Glial reactions in Parkinson's disease","volume":"23","author":"McGeer","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0055","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention","volume":"37","author":"Tansey","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2015.02.030_bb0060","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.parkreldis.2004.01.005","article-title":"Inflammation and neurodegeneration in Parkinson's disease","volume":"10","author":"McGeer","year":"2004","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1096\/fj.03-0501fje","article-title":"Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide","volume":"18","author":"Morale","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0070","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1196\/annals.1356.023","article-title":"Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway","volume":"1057","author":"Marchetti","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0075","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/archneur.60.8.1059","article-title":"Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease","volume":"60","author":"Chen","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.expneurol.2007.02.008","article-title":"Non-steroidal anti-inflammatory drugs in Parkinson's disease","volume":"205","author":"Esposito","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.expneurol.2007.05.006","article-title":"Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?","volume":"206","author":"Asanuma","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0090","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","article-title":"Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis","volume":"74","author":"Gagne","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0095","doi-asserted-by":"crossref","first-page":"81s","DOI":"10.18433\/J3T886","article-title":"Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond","volume":"11","author":"Rao","year":"2008","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tips.2007.10.010","article-title":"Delivering growth factors for therapeutics","volume":"29","author":"Anitua","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1708-8208.2009.00233.x","article-title":"Bilateral sinus elevation evaluating plasma rich in growth factors technology: a report of five cases","volume":"14","author":"Anitua","year":"2010","journal-title":"Clin. Implant. Dent. Relat. Res."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0110","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.arthro.2012.05.011","article-title":"A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis","volume":"28","author":"Sanchez","year":"2012","journal-title":"Arthroscopy"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0115","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/jcp.22274","article-title":"Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-kappaB inhibition via HGF","volume":"225","author":"Bendinelli","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0120","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/jcb.21717","article-title":"p38\/NF-kB-dependent expression of COX-2 during differentiation and inflammatory response of chondrocytes","volume":"104","author":"Ulivi","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0125","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1177\/0363546511419278","article-title":"Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes","volume":"39","author":"van Buul","year":"2011","journal-title":"Am. J. Sports Med."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0130","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1089\/scd.2013.0064","article-title":"Platelet rich plasma clot releasate preconditioning induced PI3K\/AKT\/NFkappaB signaling enhances survival and regenerative function of rat bone marrow mesenchymal stem cells in hostile microenvironments","volume":"22","author":"Peng","year":"2013","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0135","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.neurobiolaging.2014.01.009","article-title":"Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model","volume":"35","author":"Anitua","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0140","doi-asserted-by":"crossref","first-page":"e73118","DOI":"10.1371\/journal.pone.0073118","article-title":"Intranasal delivery of plasma and platelet growth factors using PRGF-Endoret system enhances neurogenesis in a mouse model of Alzheimer's disease","volume":"8","author":"Anitua","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0150","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1073\/pnas.93.10.4565","article-title":"Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity","volume":"93","author":"Przedborski","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0155","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.nbd.2011.09.017","article-title":"A30P alpha-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice","volume":"45","author":"Szego","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0160","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.neurobiolaging.2008.08.017","article-title":"Abeta accumulation in choroid plexus is associated with mitochondrial-induced apoptosis","volume":"31","author":"Vargas","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0165","doi-asserted-by":"crossref","first-page":"C675","DOI":"10.1152\/ajpcell.00437.2007","article-title":"Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism","volume":"294","author":"Crisostomo","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0170","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.0704908104","article-title":"Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease","volume":"104","author":"Ghosh","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yexmp.2008.10.004","article-title":"Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice","volume":"86","author":"Aoki","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrd3366","article-title":"Potential therapeutic uses of BDNF in neurological and psychiatric disorders","volume":"10","author":"Nagahara","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0185","doi-asserted-by":"crossref","first-page":"15596","DOI":"10.1523\/JNEUROSCI.5195-12.2013","article-title":"Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice","volume":"33","author":"Nagahara","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0190","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson's disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0195","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1172\/JCI64595","article-title":"Alzheimer's disease and insulin resistance: translating basic science into clinical applications","volume":"123","author":"De Felice","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0200","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/nm1202-793","article-title":"Serum insulin-like growth factor I regulates brain amyloid-beta levels","volume":"8","author":"Carro","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0205","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1016\/j.biomaterials.2010.03.042","article-title":"The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease","volume":"31","author":"Spuch","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0210","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","article-title":"Intranasal delivery bypasses the blood\u2013brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0215","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3171\/2009.2.JNS081199","article-title":"Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation","volume":"111","author":"Fletcher","year":"2009","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0220","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"Thorne","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0225","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/mds.25344","article-title":"Trophic factor gene therapy for Parkinson's disease","volume":"28","author":"Kordower","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0230","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/35072550","article-title":"Experimental models of Parkinson's disease","volume":"2","author":"Beal","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0235","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1007\/s11064-008-9697-6","article-title":"Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols","volume":"33","author":"Aquilano","year":"2008","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0240","first-page":"143","article-title":"Cytokines in Parkinson's disease","author":"Nagatsu","year":"2000","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0245","first-page":"135","article-title":"The parkinsonian toxin MPTP: action and mechanism","volume":"16","author":"Przedborski","year":"2000","journal-title":"Restor. Neurol. Neurosci."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0250","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/70978","article-title":"Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease","volume":"5","author":"Liberatore","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0255","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.4049\/jimmunol.1000208","article-title":"Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease","volume":"185","author":"Chung","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0260","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1073\/pnas.0837397100","article-title":"Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration","volume":"100","author":"Teismann","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0265","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-2094-3-6","article-title":"Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease","volume":"3","author":"Vijitruth","year":"2006","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0270","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.neuroscience.2008.07.031","article-title":"Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms","volume":"158","author":"Teeling","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0275","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.biopsych.2008.07.024","article-title":"Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease","volume":"65","author":"Cunningham","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2015.02.030_bb0280","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbi.2008.07.002","article-title":"Time course of hippocampal IL-1 beta and memory consolidation impairments in aging rats following peripheral infection","volume":"23","author":"Barrientos","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0285","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1471-4159.2003.02210.x","article-title":"Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation","volume":"88","author":"Dehmer","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0290","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1073\/pnas.94.14.7531","article-title":"Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease","volume":"94","author":"Hunot","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0295","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/JAD-2001-3308","article-title":"Abnormalities in oxidative processes in non-neuronal tissues from patients with Alzheimer's disease","volume":"3","author":"Gibson","year":"2001","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2015.02.030_bb0300","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.bbrc.2005.04.036","article-title":"Anti-oxidant and anti-inflammatory activities of macelignan in murine hippocampal cell line and primary culture of rat microglial cells","volume":"331","author":"Jin","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915001406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915001406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T23:21:16Z","timestamp":1566343276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365915001406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":59,"alternative-id":["S0168365915001406"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.02.030","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal PRGF-Endoret enhances neuronal survival and attenuates NF-\u03baB-dependent inflammation process in a mouse model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}